COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Clinical Trial: 20137

Trial Status: Open
Disease Type: Lung
Trial ID 20137
Sponsor ID Roche Laboratories, Inc.

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
5 Locations

Locations

Alexandria Office

Arlington Office

Fairfax Office

Gainesville Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID APG1252SU101
Sponsor ID

A Multi-Center, Phase I/II Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID U31402-A-U201
Sponsor ID HERTHENA-Lung01

A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location